A novel series of 4 00 -carbamates of 6,11-di-O-methylerythromycin A were synthesized and evaluated. These compounds have significant antibacterial activity against Gram-positive pathogens, including erythromycin-resistant but methicillin-susceptible Staphylococcus aureus, erythromycin-resistant and methicillin-resistant Staphylococcus aureus, erythromycin-resistant Streptococcus pneumoniae and Gram-negative pathogens, such as Haemophilus influenzae To our surprise, most of the derivatives tested had potent activity against most resistant bacteria. Among these, compounds 10u, 10v, 10w and 10y were found to have potent activity against most susceptible and resistant bacteria. In particular, compound 10y exhibited excellent antibacterial activity in comparison to others.
INTRODUCTION
The rapid development of antibiotic resistance among the major respiratory pathogens has created a serious problem for the effective management of respiratory tract infections. [1] [2] [3] [4] [5] [6] There is a great need for new antibiotics that address the problem of antibiotic resistance. Under these circumstances, a substantial amount study has been carried out on novel macrolides. These investigations have led to the discovery of C-4 00 -carbamate macrolides. One of the leading C-4 00 -carbamates, CP-544372 ( Figure 1, compound 1) , has demonstrated good in vitro antibacterial activity against erythromycin-susceptible and -resistant organisms. [7] [8] [9] The study of high-resolution X-ray co-crystal structures has shown that the 3-position group of macrolides is located near G2505 and C2610, and the cladinose group of erythromycin or clarithromycin is located at and fits with the cavity formed by G2505, C2610 and C2611 in domain V of the erythromycin-binding site. [9] [10] [11] The C-3 cladinose sugar attached to the 14-membered ring macrolides is believed to be responsible for the induction of macrolide resistance. This moiety also seems to be responsible for efflux resistance. 12 Fernandes et al. have reported that the induction of methylase in macrolide-resistant bacteria could be dissociated from inhibition of the bacteria by using erythromycin analogs with modification at the 4 00 position of the cladinose sugar. 13 Some studies have reported that the introduction of certain groups to the 4 00 position of the cladinose sugar results in a negligible effect on antibacterial activity. 4 00 modification can alter the relative potency of an antibiotic. 9, 14 Many new derivatives of macrolides for the effective management of erythromycin resistance have been investigated. 13 A-60565 ( Figure 1 , compound 2) has lower MICs than erythromycin does against inducibly and constitutively resistant bacteria. 9, 15 Compound 3 ( Figure 2 ) has an MIC against erythromycin-susceptible and -resistant Streptococcus pneumoniae of p0.02 and p2 mg ml À1 , respectively. 16 Compound 4 ( Figure 2 ) has potent activity against most resistant bacteria. 9 Compounds 5a and 5b ( Figure 3 ) were found to have potent activity against erythromycinresistant S. pneumoniae encoded by the erm or mef gene. 17, 18 Compounds 6a and 6b ( Figure 3 ) are effective (0.5 and 0.5 mg ml À1 ) against two strains of erythromycin-resistant S. pneumoniae, whose resistance is encoded by the erm and mef gene, respectively. 19 6,11-Di-O-methylerythromycin A ( Figure 4 , compound 7) shows excellent in vitro and in vivo antibacterial activity against Grampositive bacteria and Mycoplasma pneumoniae. 20 On the basis of the above findings, we designed novel structural 14-membered analogs of macrolide antibiotics that comprised the essential features for addressing macrolide resistance. By introduction of various amino carbonyl chain to the 4 00 -hydroxyl group of the 6,11-di-O-methylerythromycin A, a series of novel 4 00 -carbamates were obtained.
RESULTS

Chemistry
The synthetic method of 4 00 -carbamates of 6,11-di-O-methylerythromycin A is shown in Scheme 1. Our approach to get 4 00 -substituted derivatives is to regioselectively protect 2¢-OH of 6,11-di-O-methylerythromycin A (7) and to modify the 4 00 -OH. 2¢-O-acetyl 6,11-di-O-methylerythromycin A (8) provided a convenient starting material for the chemical modification leading to the 4 00 -substituted derivatives.
By using the method of Baker et al., [21] [22] [23] 8 was treated with excess 1,1-carbonyldiimidazole and sodium hydride in DMF at 0 1C for 1 h,
00 -O-acylimidazolyl erythromycin A (9) was obtained in a yield of 93%. The structure of 9 was confirmed by 13 C NMR spectrum in which two carbon peaks of carbonate and carbamate could be found at d 170.0 and d 148.5. Compounds 10a-y were prepared by reacting compound 9 with corresponding amines and 1,8-diazabicyclo [5.4 .0]undec-7-ene, followed by deprotection of the acetyl group with methanol (Scheme 1). The structures of 10a-y were determined by 13 C NMR, 1 H NMR, MS and IR spectra.
Antibacterial activity
All of the 4 00 -carbamates synthesized, as well as erythromycin, clarithromycin and azithromycin as reference compounds, were tested for in vitro antibacterial activity against three strains of Staphylococcus aureus and two strains of Streptococcus pneumoniae and Haemophilus influenzae. The activities are reported in Table 1 as MICs, which were determined by the broth microdilution method as recommended by the National Committee for Clinical Laboratory Standards.
To evaluate the potential antibacterial activity of each analog to overcome macrolide resistance, various macrolide-resistant strains were included: S. aureus ATCC25923: erythromycin-susceptible strain; S. aureus A265: erythromycin-resistant but methicillin-susceptible strain; S. aureus A333: erythromycin-resistant and methicillin-resistant strain; S. pneumoniae ATCC49619: erythromycin-susceptible strain; S. pneumoniae 3469: erythromycin-resistant strain; H. influenzae ATCC49247: ampicillin-susceptible strain; and H. influenzae 3300: ampicillin-resistant strain.
The results in Table 1 show the antibacterial activity of 4 00 -carbamates and reference compounds (erythromycin, clarithromycin and azithromycin). We presumed that chemical modification that affected the conformation would affect the ability of the antibiotics to bind to bacterial ribosomes. We obtained some new derivatives of 6,11-di-O-methylerythromycin A by modifying the 4 00 OH group with various carbamate groups such as alkylcarbamoyl, hydroxy-alkylcarbamoyl, alkoxy-alkylcarbamoyl, heterocyclic-carbamoyl, substituted benzylcarbamoyl and substituted phenethylcarbamoyl. To our surprise, most of the derivatives tested had potent activity against most resistant bacteria. Among these, compounds 10u, 10v, 10w and 10y were found to have potent activity against most susceptible and resistant bacteria. In particular, compound 10y exhibited excellent antibacterial activity in comparison to others.
DISCUSSION
A simple and efficient method for preparation of 4 00 -carbamates of macrolides was developed. These carbamates were evaluated for antibacterial activity against macrolide-susceptible and -resistant pathogens. To our surprise, most of the derivatives tested had potent activity against most resistant bacteria. Among these, compounds 10u, 10v, 10w and 10y were found to have potent activity against most susceptible and resistant bacteria. In particular, compound 10y showed excellent antibacterial activity in comparison to others. This study may present a major opportunity for the development of new macrolide antibiotics to combat effectively the growing problem of macrolide resistance.
The improved antibacterial activity against resistant bacteria achieved by these derivatives was possibly because the induction of methylase in macrolide-resistant bacteria could be dissociated from inhibition of the bacteria by using erythromycin analogs with modification at the 4 00 position of the cladinose sugar. It is worthy of notice that 4 00 -modified derivatives of 14-membered macrolides are probably the effective management of macrolide resistance, and this study may present a major opportunity for the development of new macrolide antibiotics to combat the growing problem of antibiotic resistance.
METHODS
General experimental procedures
Reagents were purchased from commercial sources. Solvents and reagents were dried and purified according to the literature methods. Melting points were uncorrected and measured on an XT-4 apparatus. IR spectra were recorded from KBr pellets at a range of 400-4000 cm À1 on a Spectrum One (Perkin Elmer, Shelton, CT, USA) spectrometer. 1 H NMR and 13 C NMR spectra were obtained on a Varian Mercury VX400 apparatus (American Varian Inc., Palo Alto, CA, USA) in CDCl 3 with TMS as internal standard. The elemental analysis (C, H, N) data were obtained from a VarioEL III elemental analyzer (German Elementar. Co., Ltd, Hanau, Germany). All the ampicillin-and erythromycin-resistant strains chosen in this test are constitutively resistant strains supplied by the Ministry of Health National Antimicrobial Resistance Investigation Net (China).
6,11-Di-O-methyl-2¢-O-acetylerythromycin A (8)
To a solution of 6,11-di-O-methylerythromycin A (7) (3.05 g, 4.0 mmol) in acetone (20 ml) at room temperature were added acetic anhydride (7.5 ml, 8 mmol, 2.0 equiv.) and K 2 CO 3 (1.10 g, 8 mmol, 2.0 equiv.). The resulting solution was allowed to stir for 24 h at the same temperature. The reaction was quenched with 5% aqueous NaHCO 3 (20 ml) and the aqueous layer was extracted with CH 2 Cl 2 (3Â20 ml). The combined organic layers 
To a solution of 8 (1.61 g, 2 mmol) in DMF (20 ml) were added NaH (0.096 g, 4 mmol, 2.0 equiv.) and carbonyldiimidazole (0.705 g, 4 mmol, 2.0 equiv.). The resulting solution was stirred at 0 1C for 1 h. The reaction was quenched with saturated NaHCO 3 (20 ml) and the aqueous layer was extracted with CH 2 Cl 2 (3Â10 ml). The combined organic layers were dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuum. The residue was purified to afford 1.67 g (93%) of 9 as a white solid: m.p. General methods for 4 00 -carbamates of 6,11-di-O-methylerythromycin A 10(a-y)
To a solution of 9 (1.35 g, 1.50 mmol) in DMF (15 ml) at 0 1C were added 1,8-diazabicyclo [5.4 .0]undec-7-ene (0.33 ml, 2.25 mmol, 1.5 equiv.) and corresponding amine (2.25 mmol, 1.5 equiv.). The resulting solution was raised to room temperature and stirred for 24 h at the same temperature. The reaction was quenched with water (30 ml) and the aqueous layer was extracted with ethyl acetate (315 ml). The combined organic layers were washed with brine, and dried over anhydrous Na 2 SO 4 , filtered. The filtrate was concentrated in vacuum to afford a crude product.
A solution of the above crude product in methanol (15 ml) was heated to 55 1C and stirred for 20 h at the same temperature. After concentrating the reaction solution in vacuum, the residue was purified by chromatography to afford products 10(a-y).
6,11-Di-O-methyl-4
00 -O-(N-propylcarbamoyl)erythromycin A (10a) 
